Cite
MLA Citation
Thomas Powles et al.. “Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.” Lancet oncology, vol. 22, no. 7, 2021, pp. 931–945. http://access.bl.uk/ark:/81055/vdc_100133914262.0x000018